Mylan NV’s latest troubles could not come at a worse time.
Two years ago, Mylan was a swaggering drugmaker on the way up, buying up rivals as it grew and diversified.
Then it faced political scrutiny over price hikes for its EpiPen allergy shot and increasing pressure on prices for the generic drugs that are the company’s backbone.
In August, Mylan cut its outlook for next year, and on Tuesday came another blow: Its No. 2 executive was one of the first two top managers accused in an industry-wide civil investigation of colluding in a “sinister” conspiracy to prop up prices.
After reaching an all-time high of US$76.06 in April 2015, its shares have been cut in half and closed on Tuesday at US$35.71, dropping 6.6 percent for the day.
Like other drugmakers, Mylan has been under increasing pressure from regulators at the US Food and Drug Administration (FDA) over the past year.
Taking up US President Donald Trump’s call to reduce drug prices, the FDA has said it will accelerate the approval of copycat drugs that will push prices down further. The agency has said it will specifically target drugs that only have a few generic competitors, trimming the industry’s already thin margins further.
The multi-year civil case against Mylan and 17 other makers of generic pills — with a dragnet that could wrap in other senior drug executives around the industry — could prove damaging.
Not only does it target Mylan president Rajiv Malik, but the alleged conduct in the complaint supposedly helped generic-drug makers preserve their margins and markets, avoiding some of the competition that has already been pressuring the industry.
In their 243-page complaint, 45 US states and Washington said that more than a dozen drugmakers worked together to share the market and avoid a “fight to the bottom.”
At industry conferences, over dinner parties and hundreds of telephone calls, e-mails and text messages, executives would agree to raise or maintain prices for specific drugs in tandem or delineate each company’s market share.
Malik is one of two senior drug executives named in the new complaint, in which the states are seeking to expand an earlier lawsuit alleging price and market fixing.
Mylan, which is also named as a defendant in the case, said it stands behind Malik and will “defend this case vigorously.”
Malik’s lawyer, Robert Cleary of Proskauer Rose LLP, said in a telephone interview that the executive “emphatically and categorically denies the allegations in the complaint” and “is confident he will be completely vindicated.”
The complaint details numerous telephone calls and e-mails between Malik and executives at closely held Indian drugmaker Emcure Pharmaceuticals Ltd and its subsidiary, Heritage Pharmaceuticals, around the time when Heritage launched an antibiotic called Doxy DR.
Mylan — then the only other generic maker with that pill on the market — agreed to give up two large accounts to Heritage, helping Heritage enter the market without putting pressure on prices, the filling said.
“Given direct involvement of executives in this case and the evidence we had implicating them, we felt as a group of antitrust enforcers that it was important to hold these individuals accountable,” Connecticut Assistant Attorney General Joseph Nielsen said on Tuesday on a conference call with reporters.
The civil investigation has run parallel to a criminal probe by the US Department of Justice that has so far led to guilty pleas from two former executives of Heritage, the Emcure subsidiary. The complaint has now expanded from six to 18 companies and 15 drugs.
Malik has worked at Mylan since 2007 and became president in 2012. Previously, he worked at Sandoz and at Ranbaxy Laboratories Ltd. One of Mylan’s senior-most executives, he is a regular speaker on quarterly earnings calls.
The company, which has a legal address in the Netherlands and is run from Canonsburg, Pennsylvania, describes him on its Web site as the leader of “all global commercial and operational activities.”
“Rajiv is easily one of the foremost generic heads out there and is a core part of Mylan leadership,” Evercore-ISI analyst Umer Raffat said.
The troubles might not end at Mylan and Emcure. On the conference call on Tuesday, Connecticut Attorney General George Jepsen suggested that other executives could be drawn in.
“Every time we kick a door in we make new discoveries,” Jepsen told reporters.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
US CONSCULTANT: The US Department of Commerce’s Ursula Burns is a rarely seen US government consultant to be put forward to sit on the board, nominated as an independent director Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday nominated 10 candidates for its new board of directors, including Ursula Burns from the US Department of Commerce. It is rare that TSMC has nominated a US government consultant to sit on its board. Burns was nominated as one of seven independent directors. She is vice chair of the department’s Advisory Council on Supply Chain Competitiveness. Burns is to stand for election at TSMC’s annual shareholders’ meeting on June 4 along with the rest of the candidates. TSMC chairman Mark Liu (劉德音) was not on the list after in December last